Recent evolution in the bispecific antibody and engineered cytokine fields

Published: 5 August 2021
Interview
Raphael Clynes
Raphael Clynes
Vice President of Translational Biology, Xencor
Raphael Clynes, MD, PhD, Vice President of Translational Biology, Xencor. Dr. Clynes is a medical oncologist/hematolo-gist and a cellular immunologist with more than 100 publications in cancer and autoimmunity. Prior to joining Xencor in 2017, Dr. Clynes evaluated combination immunotherapies in Early Clinical Development at Bristol Myers Squibb. Prior to moving to industry in 2014, Dr. Clynes led NIH-funded research programs over two decades in cancer and autoimmunity at The Rockefeller University, MSKCC and Columbia University.

Raphael Clynes, MD, PhD, Vice President of Translational Biology, Xencor. Dr. Clynes is a medical oncologist/hematolo-gist and a cellular immunologist with more than 100 publications in cancer and autoimmunity. Prior to joining Xencor in 2017, Dr. Clynes evaluated combination immunotherapies in Early Clinical Development at Bristol Myers Squibb. Prior to moving to industry in 2014, Dr. Clynes led NIH-funded research programs over two decades in cancer and autoimmunity at The Rockefeller University, MSKCC and Columbia University.

Read now